MedTrace Logo

Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

NCT01438281 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-07-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.

Conditions

  • Ocular Pain
  • Dry Eye

Interventions

DRUG

SYL1001

SYL1001 eye drops. topical administration

Sponsors & Collaborators

  • Sylentis, S.A.

    lead INDUSTRY

Principal Investigators

  • Belen Sadaba, MD, PhD · Clinica Universidad de Navarra

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-11-30
Completion
2012-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01438281 on ClinicalTrials.gov